*March 2022*
Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn’t Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.
*March 2022*
Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn’t Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.